Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study assessing the effect of food intake on CMC-001

Next Previous
Trial Profile

A study assessing the effect of food intake on CMC-001

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CMC 001 (Primary)
  • Indications Liver disorders
  • Focus Pharmacokinetics

Most Recent Events

  • 20 Oct 2021 According to an Ascelia Pharma media release, this Food Effect Study is part of the ongoing pivotal clinical program for Orviglance and will be included in the marketing authorization package to the health authorities including FDA and EMA.
  • 20 Oct 2021 Results presented in the Ascelia Pharma Media Release.
  • 20 Oct 2021 According to an Ascelia Pharma media release, final results of the Food Effect Study are expected within 4 months.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top